gtc Archives | Genomic Testing Cooperative

GTC research is being presented at ASCO 2020

GTC research is being presented at ASCO 2020 in the following three abstracts. 1. FGFR expression, fusion and mutation as detected by NGS sequencing of DNA and RNA. * 2. Measuring PD-L1 mRNA expression using targeted next generation sequencing and correlation with interferon pathway activation genes in lung and colorectal cancers. * 3. Bimodal ntrk expression and correlation with activation of PI3K/AKT pathway in lung cancer. * *Authors: Wanlong Ma, Ivan De Dios, Spiraggelos Antzoulatos, Jeffrey Estella, Maher Albitar; Genomic Testing Cooperative, Irvine, CA

Feb 26

GTC was featured in the Orange County Business Journal again

GTC featured in the Orange County Business Journal on February 3, 2020

Oct 16

GTC was honored to be featured in the Orange County Business Journal

GTC featured in the Orange County Business Journal on September 30, 2019 [Click image to enlarge]

Jul 17

Time Matters on Health Tests [TAT-NGS]

We’re always competing with ourselves on improving turn around time (TAT) because we know patients depend on the results Most studies suggest that treatment delay leads to a worse outcome Patients with cancer who have to wait longer for treatment suffer from significant anxiety and stress Physicians and patients deserve to get the results of a diagnostic test, with the shortest possible turnaround time (TAT) When dealing with cancer, clinicians and patients need to know the results of molecular testing as soon as possible. Are you waiting 21-28 days to receive your NGS results? Genomic Testing Cooperative (GTC) is using disruptive technology and will report results within 7 days of […]

Jun 26

Myelodysplastic Syndrome (MDS)

MDS is defined as ineffective hematopoiesis characterized by adequate or increased hematologic elements in bone marrow with peripheral cytopenia. Therefore, the presence of cytopenia in one or more hematologic lines is necessary for the diagnosis of MDS. However, numerous reactive conditions other than MDS can cause cytopenia and these conditions must be distinguished from MDS. While dysplasia in hematologic cells is an indication of the diagnosis of MDS, the presence of mutations along with cytopenia is the most conclusive evidence for the diagnosis of MDS. Normal individuals above the age of 50 may show mutation in some genes (ASXL1, TET2, DNMT3, and TP53), however, the level (Variant allele frequency, VAF) […]

Jun 04

Comprehensive PIK3CA Mutation Analysis

When you order GTC Breast Cancer Profile The FDA has approved Piqray (alpelisib) tablets, to be used in combination with the FDA-approved endocrine therapy fulvestrant, to treat postmenopausal women, and men, with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA-mutated, advanced or metastatic breast cancer following progression on or after an endocrine-based regimen. FDA approval of the drug was based on detecting one of 11 frequent mutations in PIK3CA. Based on our data, these 11 mutations constitute only 62.83% of the mutation we detect when Next Generation Sequencing (NGS) is used. Abnormalities in PIK3CA have been reported in approximately 30% of patients with breast cancer. […]

May 27

The FDA has Approved Drugs for FGFR Abnormalities

The FDA has approved Balversa (erdafitinib) as a treatment for adult patients with locally advanced or metastatic bladder cancer that have FGFR3 or FGFR2 abnormalities and that has progressed during or following prior platinum-containing chemotherapy. Urothelial tumors have been reported to show abnormalities in FGFR3 (22%), FGFR1 (8%), and FGFR2 (2%). These abnormalities involve mutations, fusion and amplification/overexpression. Abnormalities in FGFR can also be seen in various tumor types including lung (20%), breast (10%), melanoma (20%) rhabdomyosarcoma (7%), and cervical cancer (5%). Genomic Testing Cooperative (GTC) offers comprehensive testing of FGFR(1, 2, 3, and 4) covering mutations in all coding sequence, various fusions and expression levels. However, mutations studied in […]

May 22

GTC Presents at the 2019 ASCO Annual Meeting

Genomic Testing Cooperative (GTC) and Collaborators to Present data Resulting from its Proprietary DNA and RNA Profiling of Diffuse Large B-cell Lymphoma at the 2019 ASCO Annual Meeting Irvine, California – May 22, 2019 – Genomic Testing Cooperative, LCA. today announced that data using its unique DNA and RNA profiling will be presented at the American Society of Clinical Oncology (ASCO) annual meeting. In collaboration with University of California San Francisco, Fresno, CA and The University of Texas MD Anderson Cancer Center, Houston, TX, Genomic Testing Cooperative (GTC) used its proprietary DNA- and RNA-based profiling of diffuse large B-cell lymphoma (DLBCL) to study primary brain lymphoma. While DLBCL is common, […]

May 16

Study shows that RNA Plus DNA profiling significantly enhanced Drug Matching

Recent study published in Nature Medicine (Rodon et al, Nature Medicine volume 25, pages 751–758, 2019) showed that molecular profiling using both DNA and RNA significantly enhanced therapy recommendation and patient outcome. A third of the studied patients got drug therapy recommendation when both RNA and DNA testing was performed. Genomic testing cooperative (GTC) offers combined RNA and DNA profiling without significant increase in cost. Order GTC Solid Tumor PLUS or GTC Hematology PLUS for proper RNA and DNA profiling. In addition to DNA profiling (SNV, indels, TMB, and MSI), thorough molecular profiling requires RNA profiling. GTC RNA testing provides important information on fusion/translocation (ALK, ROS1, RET, NTRK, BCR-ABL1, EWRS1, […]

Apr 03

Cellgen Diagnostics and Genomic Testing Cooperative Partner

CELLGEN DIAGNOSTICS AND GENOMIC TESTING COOPERATIVE PARTNER TO ESTABLISH A NEW STANDARD IN CO-DEVELOPMENT OF COMPANION DIAGNOSTICS FOR CANCER THERAPIES Alliance will enable a faster and more rigorous approach to biomarker discovery and companion diagnostic co-development Irvine, CA—April 3, 2019—Cellgen Diagnostics, a leading precision diagnostics company, and Genomic Testing Cooperative (GTC), a pioneer in molecular testing, today announced a strategic collaboration to help accelerate global development of companion tests for various oncology therapeutics. The collaboration, between GTC’s Next Generation Sequencing (NGS), artificial intelligence (AI) based biomarker discovery service and Cellgen’s integrated companion diagnostics platform will provide the pharmaceutical industry a seamless integration of biomarker discovery, validation and development of in […]